Hexacosanol

Hexacosanol: A Comprehensive Reference

1. Identity and Chemical Characterization

Chemical Names and Classification

1-Hexacosanol, also known as ceryl alcohol, is a saturated primary fatty alcohol with a carbon chain length of 26. Its molecular formula is C₂₆H₅₄O, and it carries the CAS Registry Number 506-52-5. The general chemical formula of long-chain aliphatic alcohols in this family is CH₃—(CH₂)n—CH₂OH, with chain length varying from 24 to 34 carbon atoms. In standard chemical nomenclature, hexacosanol is also designated hexacosan-1-ol, and the compound is catalogued under PubChem CID 68171. Hexacosanol Reference Standard is available from the United States Pharmacopeia (USP) under catalog number USP-1305303 (CAS 506-52-5), specified for use in official USP–NF dietary supplement tests and assays.

Physical Properties

Hexacosanol is a white waxy solid at room temperature, freely soluble in chloroform, and insoluble in water. Its molecular weight is 382.7 g/mol. Due to its complete insolubility in aqueous media, these fatty alcohols are poorly soluble in lipid carriers and completely insoluble in aqueous carriers, which greatly reduces their availability in the digestive tract.

Structural Classification within Policosanol

Hexacosanol is a long-chain linear aliphatic alcohol that is part of the mixture known as policosanol, which is derived from sources such as beeswax, potatoes, rice bran, and sugar cane. Among the most important botanical long-chain (C24–C36) primary alcohols are octacosanol, triacontanol, and hexacosanol. Within standard sugar cane-derived policosanol preparations, octacosanol (62.9%), triacontanol (12.6%), and hexacosanol (6.2%) are the major components of the mixture. However, the proportion of hexacosanol varies significantly by botanical source: analysis of barley sprout extracts confirmed that hexacosanol was present at the highest levels, comprising 62–80% of the extract.

2. Natural Sources and Occurrence

Plant Epicuticular Waxes

1-Hexacosanol occurs naturally in the epicuticular wax and plant cuticle of many plant species. Policosanol-class alcohols, including hexacosanol, are naturally found in a variety of plant germs, plant and insect waxes, seeds, leaves, and grasses. Specific confirmed botanical sources include:

• Sugar cane (Saccharum officinarum): Policosanol is a natural mixture of aliphatic primary alcohols isolated from purified sugar cane wax by hydrolytic cleavage and subsequent purification. Clinically tested forms were originally derived from Cuban sugarcane wax.
• Barley sprout (Hordeum vulgare): Barley sprout contains 4.97% fat, 52.6% polysaccharide, and 34.1% protein along with a variety of vitamins, minerals, and polyphenolic compounds; hexacosanol is one such compound from the barley leaf that might improve cholesterol metabolism by decreasing cholesterol synthesis.
• Oat seedlings (Avena sativa): In Korean oat cultivars, nine policosanols were detected via GC-MS, with hexacosanol exhibiting the highest composition, constituting 88–91% of the total average content.
• Rice bran: In rice bran wax-derived policosanol, hexacosanol (C26H53OH) constitutes approximately 3.38% of the extract alongside octacosanol (48.91%) and other long-chain alcohols.
• Wheat germ oil and beeswax: Certain fatty alcohols, including hexacosanol, are derived from botanical waxes such as sugar cane wax, rice bran and other cereal waxes, and beeswax.

Industrial Production

Industrial production methods often involve extraction from natural sources like plant epicuticular waxes. In research contexts, germinated barley is grown under controlled conditions; between the 13th and 20th day after germination, young barley leaves about 10–15 cm long are harvested and freeze-dried to yield extracts enriched in hexacosanol.

3. Traditional and Historical Use

The documented traditional use of hexacosanol as an isolated compound is limited; historically, it was consumed as part of whole-wax plant extracts rather than in purified form. Hexacosanol, a long-chain aliphatic alcohol found primarily in the waxes of plants such as sugar cane, rice bran, and wheat germ, has a long-standing history in traditional medicine, particularly in Asia and South America.

Historically, hexacosanol-rich extracts—especially policosanol (a mixture dominated by hexacosanol and octacosanol)—have been employed as natural remedies to support cardiovascular health, enhance stamina, and improve general vitality. In folk medicine, sugar cane wax extracts containing hexacosanol were consumed as tonics to promote heart health and manage cholesterol levels.

Among the botanical products that have a history of use in support of human blood lipid health are certain fatty alcohols derived from botanical waxes, for example, sugar cane wax, rice bran and other cereal waxes, and beeswax. The formal pharmacological investigation of policosanol, and of hexacosanol specifically, began in Cuba during the 1980s and 1990s. Policosanol was originally tested in clinical trials for dyslipidemia in Cuba in the 1990s.

It should be noted that historical records of hexacosanol as a discrete, isolated chemical entity are largely absent; traditional preparations contained a full spectrum of long-chain fatty alcohols derived from plant waxes, and attribution of specific effects to hexacosanol alone is a product of modern analytical chemistry rather than pre-modern ethnobotanical tradition.

4. Key Constituents and Established Mechanisms of Action

AMPK Activation and HMG-CoA Reductase Inhibition

The most thoroughly investigated proposed mechanism of hexacosanol is its effect on cholesterol biosynthesis. Hexacosanol bound to the allosteric regulation site of AMP-activated protein kinase (AMPK)-β subunit and thus activated AMPK, which inhibited the activity of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase) by inhibitory phosphorylation. HMG-CoA reductase is the rate-limiting enzyme in the mevalonate pathway for cholesterol synthesis; its inhibition is the same mechanism exploited pharmacologically by statin drugs.

Another important finding was that hexacosanol (HEXA) delays the translocation to the nucleus of Sterol Regulatory Element-Binding Protein-2 (SREBP-2), which regulates HMG-CoA reductase transcription. HEXA appears to act at the post-translational level of SREBP-2, reducing its nuclear translocation and HMG-CoA reductase gene expression.

In cell culture, intracellular cholesterol measurements revealed that hexacosanol significantly reduced total cholesterol, free cholesterol, and cholesteryl ester concentrations by 38%, 33%, and 53%, respectively, compared with vehicle in lipid-loaded HepG2 hepatocytes.

Platelet Aggregation Inhibition

In addition to effects on lipid metabolism, policosanol also presents a wide range of pharmacological activities, such as reducing platelet aggregation, antiulcer properties, and anti-inflammatory effects. Policosanol derived from rice bran wax has shown potent anti-inflammatory effects by mitigating the risk of atherosclerosis through inhibition of platelet aggregation and modulation of gut microbiota composition, alleviating symptoms associated with inflammatory bowel disease. These antiplatelet effects have been attributed to the collective action of the long-chain alcohol mixture, with individual contributions of hexacosanol versus other constituents not yet fully characterized.

LDL Catabolism Stimulation

Because policosanol exerts its main effect on LDL-C, a mechanism of action through cholesterol synthesis inhibition or enhanced LDL catabolism would be conceivable. In cultured human fibroblasts, policosanol decreased carbon 14–labeled acetate incorporation into cholesterol, whereas incorporation of 14C-labeled mevalonate was not affected, suggesting that the primary site of action lies upstream of mevalonate in the cholesterol biosynthetic pathway. The exact mechanism of action of policosanol for lipid lowering has not been sufficiently elucidated, but has been associated with suppression of cholesterol synthesis as well as stimulation of the degradation of LDL cholesterol in liver cells by activating lipases.

Potential Neuroprotective Actions

Based on preclinical data, hexacosanol has been proposed to exert cytoprotective effects on neural tissue. Results from animal experiments indicate that treatment with hexacosanol can promote recovery from learning and memory impairment after damage to the brain; the restoration of cognitive capacity is of critical importance for treating neural loss due to trauma or disease. It is likely that hexacosanol has multiple actions, enhancing function of existing pathways as well as acting on degenerative processes; it is clear that hexacosanol can act on neural function to facilitate recovery of behavior in injured neurons in vivo. These findings derive from patent literature and preclinical models, not from human clinical trials.

5. Scientific Evidence by Area of Use

5.1 Lipid Metabolism and Cardiovascular Risk

Background and Early Cuban Studies

Policosanol was originally tested in clinical trials for dyslipidemia in Cuba in the 1990s; the original studies had positive outcomes suggestive of cardiovascular benefit, but subsequent trials in other populations have shown no or only marginal benefits. One notable Cuban trial reported that based on the mean values of LDL-cholesterol levels at study completion, the mean percent reductions from baseline were 27.4% and 28.1% for the 20 and 40 mg/day policosanol groups respectively, and the effects of both doses on the main efficacy variable were practically identical. Over 1,000 subjects have been studied for periods of six weeks to one year in 15 randomized, placebo-controlled trials using policosanol (5 to 20 mg per day) for lipid lowering.

Non-Cuban Randomized Controlled Trials

The picture changed substantially when independent researchers outside Cuba attempted to replicate these findings. A multicenter, randomized, double-blind, placebo-controlled trial in Germany enrolled patients with hypercholesterolemia or combined hyperlipidemia who were assigned to 10, 20, 40, or 80 mg/day of policosanol or placebo for 12 weeks. No statistically significant difference between policosanol and placebo was observed, and nonparametric tests analyzing dose-dependency yielded nonsignificant results. In none of the secondary outcome measures — namely total cholesterol, HDL-C, very low-density lipoprotein cholesterol, triglycerides, lipoprotein(a), and ratio of total or LDL-C to HDL-C — were there any significant effects of policosanol. The study authors noted that in patients with hypercholesterolemia or combined hyperlipidemia, the sugar cane-derived policosanol in usual and high doses does not demonstrate a reduction in lipid levels beyond placebo.

A North American randomized, double-blind, placebo-controlled trial in healthy adults with mild hypercholesterolemia (n = 40) administered 20 mg/day of policosanol for 8 weeks. No significant differences in the change in LDL cholesterol were observed between the placebo and policosanol groups. Also, no significant changes in secondary outcome measures, including total cholesterol, HDL cholesterol, triacylglycerol, C-reactive protein, and nuclear magnetic resonance spectroscopy-determined lipoprotein profiles were observed. The conclusion of this trial was that policosanol does not alter the serum lipid profile over an 8-week period in adults with mild hypercholesterolemia.

A systematic review and meta-analysis of trials conducted outside of Cuba similarly found that policosanol had no significant effects on total cholesterol, LDL-c, or HDL-c in four independent studies encompassing 309 participants. The majority of the existing studies showing benefit have been conducted in Cuba, and independent verification is needed before its use can be recommended.

Barley Sprout Extract (Hexacosanol-Dominant Source)

Among physiologically active substances, hexacosanol, which comprises over 70% of the policosanol compounds in barley sprout extract, was the most likely constituent of barley sprout extract to improve blood lipid metabolism and prevent atherosclerotic complications. A Korean randomized controlled trial (n = 66) tested barley sprout extract capsules (500 mg/capsule, containing approximately 7.5 mg total policosanol) against placebo once daily for 12 weeks. Subjects were randomly divided into two groups: one group consumed a single capsule of barley leaf extract daily (n = 25, mean age 42.48 years) and the other consumed placebo capsules (n = 26, mean age 40.54 years) for 12 weeks. After 12 weeks, total cholesterol and LDL-cholesterol were not lower in the barley sprout extract group compared to the placebo group (p = 0.415 and p = 0.351, respectively), and no differences in clinical or laboratory findings were observed between both groups.

Mechanistic Evidence (Preclinical)

More recently, mechanistic studies in animal models have offered a distinct line of support. Plasma and hepatic cholesterol concentrations, and hepatic steatosis, were significantly reduced in high-fat–fed mice orally administered hexacosanol (0.7 mg/kg body weight per day) for 8 weeks compared with vehicle-fed control mice, with reductions of −15% and −40% respectively. Extracts of barley and wheat seedlings containing high levels of policosanols can reduce plasma cholesterol concentrations via AMPK-dependent phosphorylation inhibition of the rate-limiting enzyme in cholesterol biosynthesis, HMGCR; in particular, hexacosanol (C26-OH), a major policosanol in barley seedlings, displayed considerable AMPK activation abilities. This mechanistic work, published in 2017, provides a plausible molecular basis for cholesterol-lowering effects, but it remains preclinical and has not been validated in human clinical trials.

Overall Evidence Assessment (Lipid Metabolism): The evidence for hexacosanol specifically, and for policosanol preparations containing hexacosanol, in lowering blood cholesterol in humans is inconsistent. Early Cuban trials reported substantial benefits, but independent randomized controlled trials in Germany, North America, and Korea did not confirm clinically meaningful lipid-lowering effects. It is not currently clear how or why this mixture of alcohols would exert health benefits; no optimal composition of policosanol has been established, and it may vary depending on the prospective indication.

5.2 Cardiovascular Effects Beyond Cholesterol

In addition to its potential effects on cholesterol, policosanol has antiplatelet effects, prevents lipoprotein peroxidation, and beneficially affects atherosclerosis development in a variety of experimental models. Policosanol has favorable effects on intermittent claudication, possibly due to its effects on platelet aggregation and endothelial function; clinical trials indicate that policosanol may have applications in the treatment of familial (type II) and diabetes-related hypercholesterolemia, as well as intermittent claudication. Evidence for these cardiovascular effects applies to the policosanol mixture as a whole; the specific contribution of hexacosanol versus co-present long-chain alcohols remains uninvestigated in dedicated human studies.

5.3 Neuroprotection and Neurological Disorders

Parkinson's Disease — Case Report

One study describes how foods rich in fisetin and hexacosanol added to a strict diet reversed most symptoms of Parkinson's disease (PD) in one patient; this is a case report involving outpatient care. The subject was a dietitian diagnosed with idiopathic PD in 2000 at the age of 53, with a history of exposure to neurotoxins and no family history of PD. The basic diet alone failed to prevent decline due to PD. In 2009, the diet was enhanced with a good dietary source of both fisetin and hexacosanol. Six months after the patient started the enhanced diet, a clinically significant improvement in symptoms was noted. This constitutes a single case report; no controlled trial evidence exists for hexacosanol in Parkinson's disease.

Preclinical Neuroprotection Data

Policosanol may have a neuroprotective effect through its antioxidant activity, and clinical trials suggest that policosanol may have a positive impact on some dementia risk factors. In addition to accelerating behavioral recovery after neural injury, hexacosanol may improve the absolute extent of recovery achievable after injury; a subject having sustained neural injury may be able to reach a higher level of behavioral function after treatment with hexacosanol than would be possible in its absence. Proposed methods for use of hexacosanol involve long-chain fatty alcohols containing from 23 to 29 carbons, or prodrug esters thereof, to promote the survival of injured neurons in the CNS, and possibly the PNS. All of these findings are from preclinical or patent-based literature; human clinical evidence for neuroprotection is absent.

5.4 Cardiac Protection — Preclinical Evidence

Animal experiments have investigated hexacosanol in combination with L-carnitine in models of cardiac anoxia. Results from these experiments show that ATP concentrations remain at normal levels only in the group of animals treated with the combination of L-carnitine and hexacosanol, achieving not only a mere additive effect, but a truly synergistic action of L-carnitine plus hexacosanol in protecting ATP of papillary muscle against the ATP-lowering effect of hypoxia. It was found that the combination of L-carnitine plus hexacosanol injected into the left ventricle was able to produce a dramatic reduction (more than 70%) in the number of ectopic contractions compared to controls, whereas administration of L-carnitine or hexacosanol alone showed only a very limited ability to reduce ectopic contractions. These results come from animal studies and have not been translated into human trials.

6. Body Systems and Health Areas Associated with Hexacosanol

• Cardiovascular system: Policosanol, the primary vehicle for hexacosanol supplementation, exhibits a wide array of beneficial properties, such as lipid-lowering, anti-inflammatory, and antioxidant activities. Associations include cholesterol regulation, platelet aggregation inhibition, and intermittent claudication.
• Hepatic system: Hexacosanol appears to act primarily in hepatic cells, where AMPK activation and SREBP-2 suppression modulate cholesterol synthesis. The hypocholesterolemic effect of hexacosanol was examined in lipid-loaded HepG2 cells and in mouse liver tissue.
• Central nervous system: Based on preclinical and case-report evidence, hexacosanol has been studied for neuroprotection, cognitive recovery after brain injury, and as a dietary component in Parkinson's disease management.
• Musculoskeletal/energetic systems: As a component of policosanol, hexacosanol is present in preparations marketed for ergogenic and physical-performance effects, following the broader profile of long-chain alcohol research; however, specific human trial evidence for hexacosanol in athletic performance is not established in the reviewed literature.

7. Dosage Forms and Reported Study Dosages

Hexacosanol is not typically sold as a single-compound supplement; it is most commonly consumed as a constituent of policosanol-standardized preparations or whole botanical extracts. Policosanol is supplied as film-coated tablets of 5 and 10 mg. The following dosages appear in the published clinical and preclinical literature:

• Policosanol mixtures (human trials): Over 1,000 subjects have been studied using policosanol at 5 to 20 mg per day for lipid lowering. The German multicenter RCT tested doses of 10, 20, 40, or 80 mg/day of policosanol for 12 weeks. The North American RCT used 20 mg/day (2 capsules of 10 mg each) for 8 weeks.
• Cuban clinical trials (policosanol): After 24 weeks, policosanol at 20 and 40 mg/day significantly lowered LDL-cholesterol by 27.4% and 28.1%, respectively in the Cuban study population.
• Barley sprout extract (hexacosanol-dominant): Freeze-dried barley sprout extract was formulated at 500 mg per capsule, with total policosanol content per capsule confirmed to be about 7.5 ± 0.3 mg, within the scope of the 5–20 mg recommended daily dose of policosanol.
• Animal model (hexacosanol isolate): Hexacosanol was orally administered at 0.7 mg/kg body weight per day for 8 weeks in high-fat–fed C57BL/6J mice.
• Policosanol daily intake range (patent formulations): A proposed daily intake range for policosanol-in-lipid compositions is from about 0.125 mg per kilogram of body weight per day to about 0.750 mg per kilogram of body weight per day, with a preferred range of about 0.3 mg/kg/day.

8. Standardization and Quality Considerations

Policosanol is a natural mixture of long-chain alcohols primarily comprising octacosanol, hexacosanol, and triacontanol. The amount of each of these alcohols can vary from product to product; each of these alcohols may have different effects on the body, and these effects may change depending on how much of each alcohol is found in the product. The combination and proportions of these alcohols that mediate benefits have not been clearly established, but preclinical studies suggest that the potential lipid modifying capacity varies across different policosanol preparations.

For quality control, a verified clinical preparation in the North American RCT was analyzed independently and found to contain 63% octacosanol (C28), 14% triacosanol (C30), 6% hexacosanol (C26), and 8% other long-chain alcohols. A concurrent analysis of the Cuban policosanol product showed it to contain 66% octacosanol, 13% triacosanol, and 7% hexacosanol.

9. Safety Considerations and Interactions

General Tolerability

Safety data for hexacosanol derives primarily from studies of policosanol mixtures in which hexacosanol is a constituent. Several animal studies using doses up to 500 mg/kg in rat models did not reveal any significant drug, reproductive, or mutagenic toxicity. Policosanol appears to be well tolerated and safe when given long-term (clinical trials up to three years). Studies in rats and mice demonstrated no adverse effects on fertility, reproduction, teratogenesis, or development at doses equivalent to 1,500 times the normal human dose of 20 mg/day.

In general, policosanol has been found to be well tolerated, with a low degree of mild, transient adverse events that showed a similar profile to placebo/control treatment. A meta-analysis of 22 trials including 1,886 participants found that the adverse event profile of policosanol was safer than the agents used in control groups.

Documented Adverse Effects

Quantifiable adverse effects reported in clinical trials include weight loss (1.8% of patients), polyuria (0.7%), and headache (0.6%). Other reported adverse effects include insomnia, polyphagia, nervousness, somnolence, dizziness, erythema, excitability, hypotension, hypertension, pruritus, skin rash, nausea, epigastric pain, diarrhea, constipation, and bleeding from the nose and gums. Increases in hepatic enzymes and creatine kinase have not been reported with policosanol. No significant adverse effects on laboratory tests including liver enzymes or renal function were observed in the reviewed clinical studies.

Drug Interactions — Anticoagulants and Antiplatelet Agents

The most clinically significant interaction concern relates to the antiplatelet properties of policosanol-class compounds. Because of its effects on platelet adhesiveness, policosanol can have additive effects with all anticoagulant and antiplatelet medications. Caution should be exercised when combining policosanol with antiplatelet or anticoagulant agents, including garlic, ginkgo, and high doses of vitamin E, as policosanol has been shown to inhibit platelet aggregation in both healthy and diseased patients.

However, in one small pharmacokinetic study, a study in 11 healthy men receiving warfarin 25 mg before and after treatment with policosanol 10 mg twice daily for 2 weeks found no effect of policosanol on the pharmacokinetics of (S)- or (R)-warfarin; policosanol also did not alter the response to warfarin on platelet aggregation. This finding does not eliminate the theoretical risk and the interactions remain an area of caution, particularly in the absence of larger dedicated pharmacokinetic trials.

Antihypertensive Drug Interactions

Animal studies suggest policosanol may increase the hypotensive effects of beta-blockers and nitroprusside. Policosanol does not interact with three types of medications used for high blood pressure: calcium-channel antagonists, diuretics, and beta-blockers based on available study data, though the animal data suggesting potentiation of beta-blocker effects should be noted.

Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

Regulatory Status

The FDA has not reviewed policosanol for safety and effectiveness in the United States. Hexacosanol Reference Standard is specified for use in official USP-NF dietary supplement tests and assays, indicating its recognition as a measurable ingredient within the dietary supplement category. It is classified under Dietary Supplements and Herbal Medicines / Botanicals-Herbal Medicines by the USP.

10. Summary of Evidence Strength

• Lipid lowering in humans: Mixed and largely negative in independent trials. Other studies attempting to confirm the cholesterol-lowering efficacy of policosanols from sugarcane have failed in both animal and human models; therefore, the hypocholesterolemic effects of sugarcane policosanols remain elusive.
• Mechanistic cholesterol lowering (AMPK/HMGCR pathway): Supported by in-vitro (HepG2) and animal data; not yet validated in human clinical trials.
• Antiplatelet effects: Supported by preclinical and some clinical data for the policosanol mixture; hexacosanol's specific contribution is not isolated.
• Neuroprotection: Supported by preclinical studies and one case report only; no randomized controlled trial evidence in humans.
• Safety profile: Generally good in clinical trials of up to three years, with mild and infrequent adverse events. Anticoagulant interaction potential warrants attention.

References

• PubChem NIH — 1-Hexacosanol | C26H54O | CID 68171
• United States Pharmacopeia — Hexacosanol Reference Standard USP-1305303
• ScienceDirect Topics — Hexacosanol Overview
• Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. American Heart Journal, 2002.
• Berthold HK et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA, 2006. PubMed.
• Dulin MF et al. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr, 2006. PubMed.
• Castano G et al. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res, 2001. PubMed.
• Byun AR et al. Effects of a Dietary Supplement with Barley Sprout Extract on Blood Cholesterol Metabolism. Evidence-Based Complementary and Alternative Medicine, 2015. PMC.
• Lee SJ et al. Hexacosanol reduces plasma and hepatic cholesterol by activation of AMP-activated protein kinase and suppression of sterol regulatory element-binding protein-2 in HepG2 and C57BL/6J mice. Nutrition, 2017. ScienceDirect.
• ResearchGate — Hexacosanol Reduces Plasma and Hepatic Cholesterol (Lee et al., 2017)
• ResearchGate — A Diet Low in Animal Fat and Rich in N-Hexacosanol and Fisetin Is Effective in Reducing Symptoms of Parkinson's Disease (case report)
• Alzheimer's Drug Discovery Foundation — Cognitive Vitality Report: Policosanol
• Systematic review: Hypercholesterolemia management beyond conventional therapy using Sugarcane Policosanol. ScienceDirect, 2025.
• Chaves MH et al. Antinociceptive and Anti-Inflammatory Effects of Octacosanol from the Leaves of Sabicea grisea var. grisea in Mice. International Journal of Molecular Sciences, 2012.
• Frontiers in Nutrition — Policosanol alleviates chronic stress-induced growth impairment via gut microbiota-metabolite interactions, 2025.
• IJPRAS — Mechanisms of Action of Policosanol in Animal and Plant Systems
• Medscape — Policosanol: Clinical Review
• Drugs.com Natural Products Database — Policosanol
• ScienceDirect Topics — Policosanol Overview (Medicine and Dentistry)
• USPTO Patent 5,135,956 — Method of using cytoprotective alcohols to treat neural disease and neural injury
• USPTO Patent 6,328,998 — Composition comprising L-carnitine or an alkanoyl L-carnitine and long-chain alkanols
• USPTO Patent 7,959,950 — Dietary supplement composition for blood lipid health
• Wikipedia — 1-Hexacosanol